Ristić S, Jovanović V, Ristić S, Radojković M
Department of Internal Diseases Dr Dragisha Mishovitsh-Dedinje, Belgrade.
Srp Arh Celok Lek. 1996 Sep-Oct;124(9-10):276-82.
Malignant lymphomas (ML) encompass about 1/6 of all malignant neoplasms. They have been divided into two major categories: Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL). While the classification of Hodgkin's disease is clearly established, classification of non-Hodgkin's lymphomas is still a histopathological problem, and requires a great pathological experience. Many morphological classifications of NHL are used in different countries. In the last few years the "Working formulation for clinical usage" is widely used. Advances in immunology allowed immunological determination of different histopathological lymphoma cell types. Progress in the field of cytogenetics discovered particular cytogenetics abnormalities in patients with different types of NHL. Modern diagnostic procedures in each patient with NHL, besides clinical staging, require a detailed morphological-immunological-cytogenetical (MIC) classification. MIC classification provides the basis for the modern therapeutical management and better estimation of prognosis and evolution of the disease.
恶性淋巴瘤(ML)约占所有恶性肿瘤的1/6。它们被分为两大类:霍奇金病(HD)和非霍奇金淋巴瘤(NHL)。虽然霍奇金病的分类已明确确立,但非霍奇金淋巴瘤的分类仍然是一个组织病理学问题,需要丰富的病理学经验。不同国家使用多种非霍奇金淋巴瘤的形态学分类。近年来,“临床应用工作分类法”被广泛应用。免疫学的进展使得能够对不同组织病理学类型的淋巴瘤细胞进行免疫学鉴定。细胞遗传学领域的进展发现了不同类型非霍奇金淋巴瘤患者存在特定的细胞遗传学异常。对于每一位非霍奇金淋巴瘤患者,现代诊断程序除了临床分期外,还需要进行详细的形态学-免疫学-细胞遗传学(MIC)分类。MIC分类为现代治疗管理以及更好地评估疾病的预后和进展提供了依据。